Meeder Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-157
Closed 2334
2021
Q3
$0 Sell
157
-1
-0.6% -$3 ﹤0.01% 2653
2021
Q2
$1K Buy
+158
New +$716 ﹤0.01% 2407
2020
Q2
Sell
-646
Closed -$6K 2501
2020
Q1
$6K Buy
646
+473
+273% +$5.43K ﹤0.01% 1733
2019
Q4
$2K Sell
173
-6,485
-97% -$94.3K ﹤0.01% 2070
2019
Q3
$114K Sell
6,658
-824
-11% -$17.3K 0.01% 763
2019
Q2
$204K Buy
7,482
+7,180
+2,377% +$164K 0.01% 576
2019
Q1
$6K Buy
302
+31
+11% +$404 ﹤0.01% 1372
2018
Q4
$3K Sell
271
-11
-4% -$141 ﹤0.01% 1529
2018
Q3
$5K Buy
+282
New +$5.41K ﹤0.01% 1341
2018
Q2
Sell
-243
Closed -$6K 1693
2018
Q1
$6K Buy
243
+69
+40% +$1.49K ﹤0.01% 1193
2017
Q4
$2K Buy
174
+126
+263% +$2.16K ﹤0.01% 1511
2017
Q3
$1K Sell
48
-146
-75% -$1.65K ﹤0.01% 1570
2017
Q2
$2K Buy
194
+42
+28% +$423 ﹤0.01% 1434
2017
Q1
$2K Buy
152
+141
+1,282% +$1.71K ﹤0.01% 1413
2016
Q4
$0 Buy
+11
New +$141 ﹤0.01% 1065

Other funds holding VYGR

Meeder Asset Management's VYGR Position: Q4 2021 in Review

Meeder Asset Management sold out of Voyager Therapeutics (VYGR) in Q4 2021, closing a stake of 157 shares.

Meeder Asset Management first reported a position in VYGR in Q4 2016 and held it in 15 quarters. The position peaked at $204K in Q2 2019. 59 funds tracked by Wall St. Rank hold VYGR as of Q4 2021.

  • Meeder Asset Management reported no remaining Voyager Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 157 Voyager Therapeutics shares in Q4 2021.
  • Meeder Asset Management first reported a position in Voyager Therapeutics in Q4 2016 and held it in 15 quarters.
  • Meeder Asset Management's Voyager Therapeutics position peaked at $204K in Q2 2019.
  • 59 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.